Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP-0130 Phase 2 Placebo-Controlled Study in Primary Open Angle Glaucoma or Ocular Hypertension
jRCT2031210584Phase 2Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in open-angle glaucoma (OAG) and ocular hypertension comparing SJP-0130 with Placebo (2 arms). Primary endpoints: Efficacy and Safety. Started Feb 2022; status: completed.
02
Drugs
netarsudil
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2031210584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210584.